Microbiome-based precision nutrition: Prebiotics, probiotics and postbiotics

Odriozola, Adrián; González, Adriana; Odriozola, Iñaki; Álvarez-Herms, Jesús; Corbi, Francesc

doi:10.1016/bs.adgen.2024.04.001

Advances in Genetics

2024

DOI: 10.1016/bs.adgen.2024.04.001

|View full text |Cite

Microbiome-based precision nutrition: Prebiotics, probiotics and postbiotics

Adrián Odriozola,

Adriana González,

Iñaki Odriozola

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 266 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options

Vallianou,

Kounatidis,

Psallida

et al. 2024

Metabolites

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) poses an emerging threat topublic health. Nonalcoholic steatohepatitis (NASH) is reported to be the most rapidly rising cause of hepatocellular carcinoma in the western world. Recently, a new term has been proposed: metabolic dysfunction-associated steatotic liver disease (MASLD). The introduction of this new terminology has sparked a debate about the interchangeability of these terms. The pathogenesis of NAFLD/MASLD is thought to be multifactorial, involving both genetic and environmental factors. Among these factors, alterations in gut microbiota and gut dysbiosis have recently garnered significant attention. In this context, this review will further discuss the gut–liver axis, which refers to the bidirectional interaction between the human gut microbiota and the liver. Additionally, the therapeutic potential of probiotics, particularly next-generation probiotics and genetically engineered bacteria, will be explored. Moreover, the role of prebiotics, synbiotics, postbiotics, and phages as well as fecal microbiota transplantation will be analyzed. Particularly for lean patients with NAFLD/MASLD, who have limited treatment options, approaches that modify the diversity and composition of the gut microbiota may hold promise. However, due to ongoing safety concerns with approaches that modulate gut microbiota, further large-scale studies are necessary to better assess their efficacy and safety in treating NAFLD/MASLD.

show abstract

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options

Vallianou,

Kounatidis,

Psallida

et al. 2024

Metabolites

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Microbiome-based precision nutrition: Prebiotics, probiotics and postbiotics

Cited by 1 publication

References 266 publications

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options

Contact Info

Product

Resources

About